Health Care·Life Sciences Tools & Services·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.06 | N/A | -86.96% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.06 | N/A | -86.96% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions and their impact on performance. They remain focused on strategic initiatives.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term growth despite short-term setbacks.
This earnings report indicates that Adaptive Biotechnologies is facing significant challenges, particularly reflected in their EPS miss. Without revenue figures or guidance, investors may be left uncertain about the company's future performance. The stock reaction is currently unavailable, but the substantial EPS miss suggests potential volatility ahead.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MONOLITHIC PWR SYS I
Oct 31, 2016